IZURALIMAB

also known as XmAb23104

Developed for: cervical carcinoma · colorectal carcinoma · endometrial carcinoma · head and neck squamous cell carcinoma · hepatocellular carcinoma · melanoma · metastatic melanoma · nasopharyngeal carcinoma
+7 more
· non-small cell lung carcinoma · renal cell carcinoma · sarcoma · small cell lung carcinoma · triple-negative breast carcinoma · undifferentiated pleomorphic sarcoma · urothelial carcinoma
Investigated by: Xencor, Inc. · ICON plc · Memorial Sloan Kettering Cancer Center · University of California, San Francisco

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 12 trials
Phase 1	NCT05695898	Feb 2023 → Apr 2024	metastatic melanoma	University of California, San Francisco	Terminated	No outcome recorded Stop: Business
Phase 1	NCT03752398	May 2019 → Feb 2024	cervical carcinoma, colorectal carcinoma, endometrial carcinoma, head and neck squamous cell carcinoma +9	Xencor, Inc.	Completed	No outcome recorded
Phase 21 trial
Phase 2	NCT05879185	Apr 2023 → Jul 2024	sarcoma	Memorial Sloan Kettering Cancer Center	Terminated	No outcome recorded

Every value below carries the sentence it was read from. 4 sources stand behind the page.

Field	Value	Cited text
Known as	IZURALIMAB	ChEMBL registry synonym — accepted as the source's own label CHEMBL4802269 ↗
Known as	XmAb23104	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05695898 ↗ 2 NCT03752398 ↗ NCT05879185 ↗
Modality	Monoclonal antibody	“Monoclonal bispecific antibody” NCT03752398 ↗
Route	Intravenous	“XmAb23104 (10 mg/kg) intravenously” NCT05879185 ↗